Medtronic PLC $MDT Stock Position Raised by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 6.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 120,034 shares of the medical technology company’s stock after purchasing an additional 7,643 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Medtronic were worth $10,464,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of MDT. 1248 Management LLC bought a new stake in shares of Medtronic during the 1st quarter valued at about $26,000. Columbia River Financial Group LLC bought a new stake in shares of Medtronic during the 1st quarter valued at about $28,000. Twin Tree Management LP bought a new stake in shares of Medtronic during the 1st quarter valued at about $29,000. Activest Wealth Management grew its position in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after buying an additional 322 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new stake in shares of Medtronic during the 1st quarter valued at about $32,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 1.0%

MDT stock opened at $95.52 on Monday. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $99.37. The firm has a market cap of $122.52 billion, a PE ratio of 26.31, a P/E/G ratio of 2.51 and a beta of 0.78. The firm has a 50 day simple moving average of $93.56 and a 200 day simple moving average of $88.74. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s payout ratio is currently 78.24%.

Analyst Ratings Changes

Several research analysts have commented on MDT shares. Wolfe Research upgraded shares of Medtronic from an “underperform” rating to a “peer perform” rating in a research report on Monday, June 30th. BTIG Research restated a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Daiwa Capital Markets upped their target price on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Wells Fargo & Company upped their target price on shares of Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.41.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.